Salute e Benessere

World Innovation Summit for Health Announces Dates for 2024 Event and Strategic…

Across two days, more than 2,000 health policy makers, innovators, researchers and practitioners will convene in Qatar to look for innovative solutions to some of the world's biggest health challenges. Across two days, more than 2,000 health policy makers, innovators, researchers and practitioners will convene inQatarto look for innovative solutions to some of the world's biggest health challenges. WISH 2024 will be the seventh edition of WISH – an event now firmly established as a vital...
PR Newswire
06/12/2023

Global Rapid Influenza Diagnostic Tests Market to Surpass $2.20 Billion by 2030…

The global rapid influenza diagnostic tests market is driven by two primary factors. Firstly, the increasing prevalence of influenza worldwide is resulting in a growing demand for rapid diagnostic tests. Influenza is a highly contagious respiratory illness that affects millions of people annually. The rapid diagnosis of influenza is crucial for effective treatment and containment of the virus. Hence, the demand for rapid influenza diagnostic tests is rapidly increasing. Theglobal rapid...
PR Newswire
06/12/2023

Cardiovascular Ultrasound Market to Reach $4.2 Billion by 2032, exhibiting a…

Request Sample of the Report on Cardiovascular Ultrasound Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/2827 Request Sample of the Report on Cardiovascular Ultrasound Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/2827 Prime determinants of growth Rise in prevalence of chronic cardiovascular diseases such as coronary artery disease, cardiac arrythmias, and others is anticipated to boost the growth of market. However, high...
PR Newswire
06/12/2023

GENFIT Announces Publication in the Journal of Hepatology on the Accurate…

The paper published inJournal of Hepatologydemonstrates that NIS2+™ technology could significantly reduce liver biopsy failure rate and maximizes accuracy of patient selection for MASH 1clinical trialsGrowing body of clinical evidence: this is the third paper on NIS2+™ that has been published in a leading medical journal in 2023 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 6, 2023 -GENFIT (Nasdaq and Euronext: GNFT), a...
Nasdaq GlobeNewswire
06/12/2023

Skincare Awareness and Moisturizer Demand Propel Dry Skin Care Market to US$…

To access in-depth market analysis updates, historical data (2019 to 2023), and projected market size (2024 to 2034), request your complimentary sample PDF report today. To access in-depth market analysis updates, historical data (2019 to 2023), and projected market size (2024 to 2034),request your complimentary sample PDF report today. The dry skin condition, also known as xeroderma, is prevalent in the populations of several countries. Dry skin can make the skin feel rough,...
PR Newswire
06/12/2023

Parkinson's Disease Therapeutics Market revenue to hit USD 12.32 Billion by…

Parkinson's disease (PD) is a progressive neurodegenerative condition affecting the dopamine-producing cells in the substantia nigra region of the brain. It manifests through various motor and non-motor symptoms, including tremors, rigidity, cognitive impairment, and sleep disturbances. The global prevalence of PD is on the rise, reaching an estimated 10 million individuals in 2020 and projected to reach 12 million by 2030 and 14 million by 2040. This increase is primarily attributed to factors…
PR Newswire
06/12/2023

Microcarriers Market Worth $3.3 Billion | MarketsandMarkets

Browse in-depth TOC on "Microcarriers Market" Browse in-depth TOC on "Microcarriers Market" 499 - Tables 52 - Figures 433 - Pages Microcarriers Market Scope: The consumables segment accounted for the largest market share by product in the microcarriers market in 2022. By product, the microcarriers market has been further categorized as consumables (media, reagents, microcarrier beads, and other consumables), equipment (bioreactors, culture vessels, filtration...
PR Newswire
06/12/2023

LTS receives grant of $1.2 Million to support the development of thermostable…

At the World Vaccine Congress in Barcelona, LTS recently presented pre-clinical data from an mRNA/LNP MAP-based vaccination against rabies, from a collaboration with a biopharmaceutical company. This successful pre-clinical study with mRNA/LNP vaccine against rabies demonstrated that the cold-chain requirements can be reduced from -80ºC to 2-8ºC by using a MAP instead of an injectable formulation. At the World Vaccine Congress inBarcelona, LTS recently presented pre-clinical data from an...
PR Newswire
06/12/2023

Micro Medical Solutions Announces Completion of Enrollment in the STAND Pivotal…

STAND (A Clinical Evaluation of the MicroSTent PeripherAl Vascular SteNt in subjects with Arterial Disease Below the Knee) enrolled its final patient earlier this month marking the completion of the study. MicroStent is a vascular stent specifically designed to achieve and maintain tibioperoneal arterial patency improving blood flow and wound healing for below-the-knee amputation reduction in patients with critical limb ischemia (CLI) resulting from progressive peripheral artery disease (PAD)…
PR Newswire
06/12/2023

SaniSure earns EcoVadis Silver Rating, recognizing strong commitment to…

EcoVadis is a trusted platform that assesses the environmental and social performance of companies across various industries worldwide. SaniSure's overall score of 60 positions the company ahead of nearly 80% of the biomanufacturing industry. EcoVadis is a trusted platform that assesses the environmental and social performance of companies across various industries worldwide. SaniSure's overall score of 60 positions the company ahead of nearly 80% of the biomanufacturing industry. "This...
PR Newswire
06/12/2023

Infusion Pumps Market to be Worth USD 15.6 billion by 2031| Transparency Market…

Infusion pumps with remote monitoring are replacing traditional infusion pumps, which can be controlled wirelessly to control and monitor intravenous drips. Fluids can be administered with infusion pumps using very small volumes or at precisely programmed rates or intervals, offering several significant advantages over manual administration of fluids. These pumps can deliver hormones, antibiotics, chemotherapeutic drugs, and pain relievers to patients as needed, including insulin and other…
PR Newswire
06/12/2023

Velocity Clinical Research expands to Poland

Strong pipeline of Polish acquisition targets by end of 2023Hires ex-Parexel Global Head Site Solutions to lead Polish expansionLONDON, Dec.06, 2023(GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, announced it has expanded into Poland, acquiring its first site, ClinMedica Research. Located in Skierniewice, which is halfway between Warsaw and Lodz, the site marks the first in a series of key acquisitions targeted by...
Nasdaq GlobeNewswire
06/12/2023

Protein Engineering Market to Reach $7.7 Billion, Globally, by 2032 at 13.2%…

Request Sample of the Report on Protein Engineering Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/1129 Request Sample of the Report on Protein Engineering Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/1129 Prime determinants of growth Increasing R&D activities in the biopharmaceutical industry, technological advancements in protein engineering, and increase in developmental strategies in protein engineering by key...
PR Newswire
06/12/2023

CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer…

CDR-Life Inc.today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA). Licensed to Boehringer Ingelheim, BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology. The Phase 1 study ( NCT06006585 ) is evaluating the safety, tolerability and pharmacokinetics of intravitreal single...
Nasdaq GlobeNewswire
06/12/2023

Abzena Partners with ProteoNic to Offer Enhanced CHO Cell Line Platform for…

For the past 20 years, Abzena has built a strong reputation for producing high-yielding mammalian cell lines for protein targets. By applying the 2G UNic vector technology to their existing CHO platform, Abzena will not only increase product development efficiency and capacity but also reduce the cost of goods for customers in early-stage development. For the past 20 years, Abzena has built a strong reputation for producing high-yielding mammalian cell lines for protein targets. By applying…
PR Newswire
06/12/2023

Ariceum Therapeutics announces granting of US and Canadian patents for its…

Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics said: "We are pleased that this IP has been granted so soon after our recent acquisition of Theragnostics, highlighting our progress and commitment to developing a pipeline of targeted radiotherapy innovations. We are proud to be contributing with this IP to the success of PSMA diagnostics, specifically Locametz, which represents an alternative pathway for PMSA PET imaging of patients." Manfred Rüdiger, Chief Executive…
PR Newswire
06/12/2023

VALNEVA Declaration of shares and voting rights - November 30, 2023

VALNEVADeclaration of shares and voting rightsNovember 30, 2023__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: December 6, 2023 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the...
Nasdaq GlobeNewswire
06/12/2023

LifeArc announces £5 million drug repurposing programme for motor neuron disease

MEDIA RELEASELifeArc announces £5 million drug repurposing programme for motor neuron disease LifeArc is launching new £5m programme to help find new treatments for motor neuron disease (MND).The programme is seeking applications from the international MND research community for research projects looking at repurposed drugs and drug combinations to tackle the neurodegenerative condition.The programme will verify the potential effectiveness of promising treatments to improve...
Nasdaq GlobeNewswire
06/12/2023

Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of…

Press ReleaseStockholm, Sweden, December 6, 2023 CADENCE Phase 2 trial will evaluate vididencel in combination with oral azacitidineRandomized controlled trial in 40 patients, with potential to extend up to 140 patientsCollaboration with ALLG to significantly strengthen Mendus clinical trial network Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the company has entered into a...
Nasdaq GlobeNewswire
06/12/2023

BioSenic on its way to find the necessary funds to perform its key clinical…

PRESS RELEASE – INSIDE INFORMATION Biosenic signs term sheet with SPRIM Global Investments (TrialCap fund) for up to USD 8 million debt financing and USD 800,000 equity investment as a first decisive, financing step towards a Phase 3 clinical trial for its ground-breaking auto-immune medication, a first-in-class drug oral arsenic salt.Mont-Saint-Guibert, Belgium, December 6, 2023, 7.00 am CEST – BIOSENIC(Euronext Brussels and Paris: BIOS), the clinical-stage company...
Nasdaq GlobeNewswire
06/12/2023

Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and…

Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressVIVIAD and VIVA-MIND studies both advancing as planned at 600mg twice daily following positive DSMB decisions; VIVIAD safety update with cut-off as of November 20, 2023, confirms low level of discontinuationsOn track to report VIVIAD final topline Phase 2b data during end of Q1/2024 Commenced preparations for VIVALONG, an open-label extension studyUnveiling focused...
Nasdaq GlobeNewswire
06/12/2023

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior…

Ad hoc announcement pursuant to Art. 53 LRApproval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients 1-5 In APPLY-PNH, patients who switched to Fabhalta experienced superior increases of hemoglobin levels ≥ 2 g/dL (82.3% vs. 0%) and hemoglobin level ≥ 12 g/dL (67.7% vs. 0%), both in the absence of red blood cell transfusions, vs. patients who continued on...
Nasdaq GlobeNewswire
06/12/2023

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; December 5, 2023 –Genmab A/S(Nasdaq: GMAB) will increase its share capital by 7,054 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 1,106 shares at DKK 1,025.00, 3,453 shares at DKK 1,145.00, 300 shares at DKK 1,147.50, 85...
Nasdaq GlobeNewswire
05/12/2023

A Comprehensive Analysis of Rare Diseases Market With a Focus on Homozygous…

DelveInsight has expertise in the rare disease market with an experienced team handling the rare disease domain proficiently. DelveInsight has recently released a series of epidemiology-based market reports on rare diseases including Homozygous Familial Hypercholesterolemia, Heparin-induced Thrombocytopenia, Post-Bariatric Hypoglycemia, IgG4-related Disease, and ANCA-associated Vasculitis. These reports include a comprehensive understanding of current treatment practices, emerging drugs, market…
PR Newswire
05/12/2023
Altri  Comunicati